Cargando…
Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France
The objective of this study was to assess the clinical impact and financial costs of next-generation sequencing (NGS) in 5 categories of pediatric and adult hematological cancers. NGS prescriptions were prospectively collected from 26 laboratories, with varied technical and reporting practice (all o...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455455/ https://www.ncbi.nlm.nih.gov/pubmed/37637995 http://dx.doi.org/10.1097/HS9.0000000000000943 |
_version_ | 1785096455163215872 |
---|---|
author | Darlington, Meryl Sujobert, Pierre Kosmider, Olivier Luque Paz, Damien Kaltenbach, Sophie Figeac, Martin Hayette, Sandrine Mezaour, Nadia Coquerelle, Séverine Alary, Anne-Sophie Bidet, Audrey Le Bris, Yannick Delabesse, Eric Davi, Frédéric Preudhomme, Claude Durand-Zaleski, Isabelle Macintyre, Elizabeth Alame, Mélissa Baran-Marzak, Fanny Berger, Marc G. Bories, Dominique Caye-Eude, Aurélie Cayuela, Jean-Michel Cornillet-Lefebvre, Pascale Delhommeau, François Estienne-Felix, Marie-Hélène Etancelin, Pascaline Flandrin-Gresta, Pascale Lippert, Eric Marzac, Christophe Miguet, Laurent Pastoret, Cédric Raynaud, Sophie Rizzo, David |
author_facet | Darlington, Meryl Sujobert, Pierre Kosmider, Olivier Luque Paz, Damien Kaltenbach, Sophie Figeac, Martin Hayette, Sandrine Mezaour, Nadia Coquerelle, Séverine Alary, Anne-Sophie Bidet, Audrey Le Bris, Yannick Delabesse, Eric Davi, Frédéric Preudhomme, Claude Durand-Zaleski, Isabelle Macintyre, Elizabeth Alame, Mélissa Baran-Marzak, Fanny Berger, Marc G. Bories, Dominique Caye-Eude, Aurélie Cayuela, Jean-Michel Cornillet-Lefebvre, Pascale Delhommeau, François Estienne-Felix, Marie-Hélène Etancelin, Pascaline Flandrin-Gresta, Pascale Lippert, Eric Marzac, Christophe Miguet, Laurent Pastoret, Cédric Raynaud, Sophie Rizzo, David |
author_sort | Darlington, Meryl |
collection | PubMed |
description | The objective of this study was to assess the clinical impact and financial costs of next-generation sequencing (NGS) in 5 categories of pediatric and adult hematological cancers. NGS prescriptions were prospectively collected from 26 laboratories, with varied technical and reporting practice (all or only significant targets). Impact was defined by the identification of (1) an actionable mutation, (2) a mutation with prognostic and/or theranostic value, and/or (3) a mutation allowing nosological refinement, reported by local investigators. A microcosting study was undertaken in 4 laboratories, identifying the types and volumes of resources required for each procedural step. Individual index prescriptions for 3961 patients were available for impact analysis on the management of myeloid disorders (two thirds) and, mainly mature B, lymphoid disorders (one third). NGS results were considered to impact the management for 73.4% of prescriptions: useful for evaluation of prognostic risk in 34.9% and necessary for treatment adaptation (actionable) in 19.6%, but having no immediate individual therapeutic impact in 18.9%. The average overall cost per sample was 191 € for the restricted mature lymphoid amplicon panel. Capture panel costs varied from 369 € to 513 €. Unit costs varied from 0.5 € to 5.7 € per kb sequenced, from 3.6 € to 11.3 € per target gene/hot-spot sequenced and from 4.3 € to 73.8 € per target gene/hot-spot reported. Comparable costs for the Amplicon panels were 5–8 € per kb and 10.5–14.7 € per target gene/hot-spot sequenced and reported, demonstrating comparable costs with greater informativity/flexibility for capture strategies. Sustainable funding of precision medicine requires a transparent discussion of its impact on care pathways and its financial aspects. |
format | Online Article Text |
id | pubmed-10455455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-104554552023-08-26 Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France Darlington, Meryl Sujobert, Pierre Kosmider, Olivier Luque Paz, Damien Kaltenbach, Sophie Figeac, Martin Hayette, Sandrine Mezaour, Nadia Coquerelle, Séverine Alary, Anne-Sophie Bidet, Audrey Le Bris, Yannick Delabesse, Eric Davi, Frédéric Preudhomme, Claude Durand-Zaleski, Isabelle Macintyre, Elizabeth Alame, Mélissa Baran-Marzak, Fanny Berger, Marc G. Bories, Dominique Caye-Eude, Aurélie Cayuela, Jean-Michel Cornillet-Lefebvre, Pascale Delhommeau, François Estienne-Felix, Marie-Hélène Etancelin, Pascaline Flandrin-Gresta, Pascale Lippert, Eric Marzac, Christophe Miguet, Laurent Pastoret, Cédric Raynaud, Sophie Rizzo, David Hemasphere Article The objective of this study was to assess the clinical impact and financial costs of next-generation sequencing (NGS) in 5 categories of pediatric and adult hematological cancers. NGS prescriptions were prospectively collected from 26 laboratories, with varied technical and reporting practice (all or only significant targets). Impact was defined by the identification of (1) an actionable mutation, (2) a mutation with prognostic and/or theranostic value, and/or (3) a mutation allowing nosological refinement, reported by local investigators. A microcosting study was undertaken in 4 laboratories, identifying the types and volumes of resources required for each procedural step. Individual index prescriptions for 3961 patients were available for impact analysis on the management of myeloid disorders (two thirds) and, mainly mature B, lymphoid disorders (one third). NGS results were considered to impact the management for 73.4% of prescriptions: useful for evaluation of prognostic risk in 34.9% and necessary for treatment adaptation (actionable) in 19.6%, but having no immediate individual therapeutic impact in 18.9%. The average overall cost per sample was 191 € for the restricted mature lymphoid amplicon panel. Capture panel costs varied from 369 € to 513 €. Unit costs varied from 0.5 € to 5.7 € per kb sequenced, from 3.6 € to 11.3 € per target gene/hot-spot sequenced and from 4.3 € to 73.8 € per target gene/hot-spot reported. Comparable costs for the Amplicon panels were 5–8 € per kb and 10.5–14.7 € per target gene/hot-spot sequenced and reported, demonstrating comparable costs with greater informativity/flexibility for capture strategies. Sustainable funding of precision medicine requires a transparent discussion of its impact on care pathways and its financial aspects. Lippincott Williams & Wilkins 2023-08-24 /pmc/articles/PMC10455455/ /pubmed/37637995 http://dx.doi.org/10.1097/HS9.0000000000000943 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Darlington, Meryl Sujobert, Pierre Kosmider, Olivier Luque Paz, Damien Kaltenbach, Sophie Figeac, Martin Hayette, Sandrine Mezaour, Nadia Coquerelle, Séverine Alary, Anne-Sophie Bidet, Audrey Le Bris, Yannick Delabesse, Eric Davi, Frédéric Preudhomme, Claude Durand-Zaleski, Isabelle Macintyre, Elizabeth Alame, Mélissa Baran-Marzak, Fanny Berger, Marc G. Bories, Dominique Caye-Eude, Aurélie Cayuela, Jean-Michel Cornillet-Lefebvre, Pascale Delhommeau, François Estienne-Felix, Marie-Hélène Etancelin, Pascaline Flandrin-Gresta, Pascale Lippert, Eric Marzac, Christophe Miguet, Laurent Pastoret, Cédric Raynaud, Sophie Rizzo, David Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France |
title | Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France |
title_full | Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France |
title_fullStr | Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France |
title_full_unstemmed | Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France |
title_short | Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France |
title_sort | targeted high-throughput sequencing for hematological malignancies: a gbmhm survey of practice and cost evaluation in france |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455455/ https://www.ncbi.nlm.nih.gov/pubmed/37637995 http://dx.doi.org/10.1097/HS9.0000000000000943 |
work_keys_str_mv | AT darlingtonmeryl targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT sujobertpierre targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT kosmiderolivier targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT luquepazdamien targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT kaltenbachsophie targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT figeacmartin targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT hayettesandrine targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT mezaournadia targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT coquerelleseverine targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT alaryannesophie targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT bidetaudrey targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT lebrisyannick targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT delabesseeric targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT davifrederic targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT preudhommeclaude targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT durandzaleskiisabelle targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT macintyreelizabeth targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT alamemelissa targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT baranmarzakfanny targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT bergermarcg targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT boriesdominique targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT cayeeudeaurelie targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT cayuelajeanmichel targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT cornilletlefebvrepascale targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT delhommeaufrancois targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT estiennefelixmariehelene targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT etancelinpascaline targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT flandringrestapascale targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT lipperteric targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT marzacchristophe targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT miguetlaurent targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT pastoretcedric targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT raynaudsophie targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance AT rizzodavid targetedhighthroughputsequencingforhematologicalmalignanciesagbmhmsurveyofpracticeandcostevaluationinfrance |